- Home
- MLYS
as 04-18-2025 1:39pm EST
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | RADNOR |
| Market Cap: | 893.0M | IPO Year: | 2023 |
| Target Price: | $33.00 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.24 - $18.38 | Next Earning Date: | 05-08-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Mineralys Therapeutics Inc. (MLYS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Congleton Jon | MLYS | Chief Executive Officer | Apr 11 '25 | Sell | $12.19 | 15,319 | $186,802.95 | 862,289 | |
| Levy Adam Scott | MLYS | CFO and Secretary | Apr 11 '25 | Sell | $12.06 | 10,757 | $129,684.24 | 215,340 | |
| Rodman David Malcom | MLYS | Chief Medical Officer | Apr 1 '25 | Sell | $15.93 | 55,771 | $879,008.48 | 139,110 | |
| RA CAPITAL MANAGEMENT, L.P. | MLYS | Director | Mar 13 '25 | Buy | $13.50 | 1,296,296 | $17,499,996.00 | 4,280,051 | |
| AKKARAJU SRINIVAS | MLYS | Director | Mar 13 '25 | Buy | $13.50 | 600,000 | $8,100,000.00 | 5,674,916 | |
| Samsara BioCapital GP, LLC | MLYS | 10% Owner | Mar 13 '25 | Buy | $13.50 | 600,000 | $8,100,000.00 | 5,674,916 |
Latest Mineralys Therapeutics Inc. News
MLYS Breaking Stock News: Dive into MLYS Ticker-Specific Updates for Smart Investing
Simply Wall St.
6 days ago
Institutional investors must be pleased after a 8.1% gain last week that adds to Mineralys Therapeutics, Inc.'s (NASDAQ:MLYS) one-year returns
MT Newswires
15 days ago
Mineralys Therapeutics Insider Sold Shares Worth $879,008, According to a Recent SEC Filing
GlobeNewswire
20 days ago
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25)
Insider Monkey
24 days ago
Mineralys Therapeutics, Inc. (MLYS): Among Stocks Receiving the Most Insider Love in March
GlobeNewswire
24 days ago
Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET
Insider Monkey
a month ago
Is Mineralys Therapeutics, Inc. (MLYS) a Pump and Dump Stock Favored by Hedge Funds?
GlobeNewswire
a month ago
Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
MT Newswires
a month ago
Mineralys Therapeutics Insider Bought Shares Worth $8,100,000, According to a Recent SEC Filing
Compare MLYS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MLYS Mineralys Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.